Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05165355
What this trial is testing

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Who this might be right for
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Tongji University 90
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07822984
What this trial is testing

Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerSBRTNSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 374
Testing effectiveness (Phase 2)Looking for participantsNCT05805631
What this trial is testing

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungEpidermal Growth Factor ReceptorLeptomeningeal Metastasis
Taipei Veterans General Hospital, Taiwan 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07807722
What this trial is testing

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)EGFRNeoadjuvant Therapy
Hubei Cancer Hospital 29
Not applicableNot Yet RecruitingNCT07697716
What this trial is testing

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Gene Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Testing effectiveness (Phase 2)Ended earlyNCT06186076
What this trial is testing

Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Mutant Advanced Non-Small Cell Lung Cancer
Therapex Co., Ltd 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03392246
What this trial is testing

Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Dana-Farber Cancer Institute 25
Testing effectiveness (Phase 2)UnknownNCT04517526
What this trial is testing

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

Who this might be right for
Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT
Shanghai Cancer Hospital, China 60
Early research (Phase 1)Looking for participantsNCT05142189
What this trial is testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BioNTech SE 320
Testing effectiveness (Phase 2)Ended earlyNCT02147990
What this trial is testing

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 318
Testing effectiveness (Phase 2)UnknownNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)UnknownNCT02960607
What this trial is testing

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chinese Academy of Medical Sciences 25
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Large-scale testing (Phase 3)Looking for participantsNCT04181060
What this trial is testing

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03667820
What this trial is testing

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center 41
Testing effectiveness (Phase 2)Ended earlyNCT03091491
What this trial is testing

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
National Cancer Centre, Singapore 31
Large-scale testing (Phase 3)UnknownNCT02518802
What this trial is testing

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Who this might be right for
Lung Neoplasms
Tang-Du Hospital 220
Next Page